ENA Respiratory.png
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
September 28, 2021 08:00 ET | ENA Respiratory
-- ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost...
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
July 13, 2021 08:00 ET | ENA Respiratory
-- First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal...
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
June 15, 2021 08:00 ET | ENA Respiratory
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051Company appoints President and Chief Scientific Officer of...